{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-044001","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.248639+00:00","generated_at":"2026-05-30T03:38:50.867277+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)","bullets":["Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.","Net loss $9.7M ($0.32 per diluted share) vs $6.0M ($0.20) prior year; operating loss $10.2M.","Adjusted EBITDA loss $8.8M; cash and securities $37.7M as of Sept 30, 2024.","FDA 510(k) review ongoing for Co-Dx PCR platform; TB, respiratory, HPV multiplex tests in pipeline.","India oligonucleotide (Co-Primers) mfg facility inauguration expected early Dec 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-044001","json":"https://secwatch.observer/filing/0001493152-24-044001.json","markdown":"https://secwatch.observer/filing/0001493152-24-044001.md","text":"https://secwatch.observer/filing/0001493152-24-044001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224044001/0001493152-24-044001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315224044001/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:38:50.867277+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}